Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy

References

• CroomKPloskerGSpotlight on the pharmacoeconomics of escitalopram in depressionCNS Drugs20041846947315139801
   PubMed Web of Science ®Google Scholar
• MooreJDBonaJRDepression and dysthymiaMed Clin North Am20018563164411349477
   PubMed Web of Science ®Google Scholar
• GirolamoGPolidoriGMorosiniPPrevalence of common mental disorders in Italy: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) projectActa Psychiatr Scand Suppl2004420212715128384
   PubMedGoogle Scholar
• ColomboGDi MatteoSNel Trattamento della Depressione Maggiore Nelle Diverse Regioni Italiane: Il Ruolo di Venlafaxina [Budget Impact Analysis in the Treatment of Major Depressive Disorder on Italian Regions: The Role of Venlafaxine]MilanW.H.E.RE. Medical Press Srl2009 Italian.
   Google Scholar
• BattagliaADubiniAMannheimerRPancheriPDepression in the Italian community: epidemiology and socio-economic implicationsInt Clin Psycho pharmacol200419135142
   Web of Science ®Google Scholar
• GreenbergPEKesslerRCBirnbaumHGThe economic burden of depression in the United States: how did it change between 1990 and 2000?J Clin Psychiatry2003641465147514728109
   PubMed Web of Science ®Google Scholar
• StoudemireAFrankRHedemarkNKamletMBlazerDThe economic burden of depressionGen Hosp Psychiatry198683873943491775
   PubMed Web of Science ®Google Scholar
• KindPSorensenJThe costs of depressionInt Clin Psychopharmacol199371911958468441
   PubMed Web of Science ®Google Scholar
• FrankLRevickiDASorensenS VThe economics of selective serotonin reuptake inhibitors in depression: a critical reviewCNS Drugs200115598311465013
   PubMed Web of Science ®Google Scholar
• PanzarinoPJNashDBCost-effective treatment of depression with selective serotonin reuptake inhibitorsAm J Manag Care2001717318411216334
   PubMed Web of Science ®Google Scholar
• RevickiDASimonGEChanKDepression, health-related quality of life, and medical cost outcomes of receiving recommended levels of antidepressant treatmentJ Fam Pract1998474464529866670
   PubMed Web of Science ®Google Scholar
• EllisPAustralian and New Zealand clinical practice guidelines for the treatment of depressionAust N Z J Psychiatry20043838940715209830
   PubMed Web of Science ®Google Scholar
• National Guideline Clearinghouse: DepressionThe treatment and management of depression in adults [webpage on the Internet]. Guideline summaryLondon, UKNational Institute for Health and Clinical Excellence2009 Available from: http://guideline.gov/content.aspx?id=15521Accessed December 17, 2012
   Google Scholar
• CiprianiAFurukawaTASalantiGComparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysisLancet200937374675819185342
   PubMed Web of Science ®Google Scholar
• TrifiròGTillatiSSpinaEA nationwide prospective study on prescribing pattern of antidepressant drugs in Italian primary careEur J Clin PharmacolEpub 6 17, 2012
   Google Scholar
• WesslingARamsbergJDepression: The Review of AntidepressantsSolna, SwedenThe Dental and Pharmaceutical benefits Agency2008 Available from: http://www.tlv.se/Upload/genomgangen/reviewantidepressants.pdfAccessed November 21, 2012
   Google Scholar
• GaynesBRushAMadhukarTWisniewskiSSpencerDFavaMThe STAR*D study: treating depression in the real worldCleve Clin J Med200875576618236731
   PubMed Web of Science ®Google Scholar
• GilchristGGunnJObservational studies of depression in primary care: what do we know?BMC Fam Pract200782817493280
   PubMed Web of Science ®Google Scholar
• LothgrenMHemelsMFrancoisCJoenssonBACost-effectiveness analysis of escitalopram as first line treatment of depression in SwedenPrimary Care Psychiatry20049153162
   Google Scholar
• KhanAKhanSRLeventhalRMBrownWASymptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: a replication analysis of the Food and Drug Administration DatabaseInt J Neuropsychopharmacol2001411311811466159
   PubMed Web of Science ®Google Scholar
• Agenzia Italiana del Farmaco [homepage on the Internet]RomeAgenzia Italiana del Farmaco Available from: http://www.agenziafarmaco.gov.it/Accessed November 21, 2012
   Google Scholar
• WHOCC [homepage on the Internet] International language for drug utilization researchOslo, NorwayWorld Health Organization Collaborating Center for Drug Statistics Methodologyupdated 5 4, 2012 Available from: http://www.whocc.no/Accessed November 21, 2012
   Google Scholar
• SobockiPEkmanMAgrenHRunesonBJönssonBThe mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depressionInt J Clin Pract20066079179816846399
   PubMed Web of Science ®Google Scholar
• PevelerRKendrickTBuxtonMA randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramineHealth Technol Assess200591134 iii.15876362
   PubMed Web of Science ®Google Scholar
• JamisonDTBremanJGMeashamARCost-effectiveness analysisPriorities in HealthWashington, DCWorld Bank2006 Available from: http://www.ncbi.nlm.nih.gov/books/NBK10253/Accessed November 21, 2012
   Google Scholar
• LucioniCRavasioRCome valutare i risultati di uno studio farmacoeconomico? How to evaluate the results of a pharmacoeconomic analysis?PharmacoEconomics – Italian Research Articles20043121130 Italian.
   Google Scholar
• CapriSRicciardiWAdvate nel trattamento dell’emofillia A – analisi costo-efficacia della terapia on-demand versus profilassi basata sull’emivita del prodotto. [Advate in the treatment of emoflia A – cost-effectiveness of an on-demand therapy versus a prophylaxis based on the half-life of the product]Ital J Public Health201186167 Italian.
   Google Scholar
• UK’s NICE unlikely to bow to new pricing suggestionsFinancial Times5102012
   Google Scholar
• RawlinsMDCulyerAJNational Institute for Clinical Excellence and its value judgementsBMJ200432922422715271836
   PubMed Web of Science ®Google Scholar
• CulyerAJIntroductionTowseAPritchardCDevlinNCost Effectiveness Thresholds: Economic and Ethical IssuesLondon, UKKings Fund and Office of Health Economics2002
   Google Scholar
• Palisade CorporationMaker of Risk and Decision Analysis Software using Monte Carlo Simulation [homepage on the Internet]Ithaca, NYPalisade Corporation2012 Available from: http://www.palisade.com/Accessed November 21, 2012
   Google Scholar
• CEA Registry [homepage on the Internet]Boston, MACost-Effectiveness Analysis Registry Available from: https://research.tufts-nemc.org/cear4/Accessed November 21, 2012
   Google Scholar
• CiprianiASantilliCFurukawaTAEscitalopram versus other antidepressive agents for depressionCochrane Database Syst Rev20092CD00653219370639
   PubMed Web of Science ®Google Scholar
• SullivanP WValuckRSaseenJMacFallHMA comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactionsCNS Drugs20041891193215521793
   PubMed Web of Science ®Google Scholar
• NuijtenMBrignoneMMarteauFden BoerJHoencampECost-effectiveness of escitalopram in major depressive disorder in the Dutch health careClin Ther2012341364137822578310
   PubMed Web of Science ®Google Scholar
• EvansCThe use of consensus methods and expert panels in pharmacoeconomic studies: practical applications and methodological shortcomingsPharmacoeconomics19971212112910169665
   PubMed Web of Science ®Google Scholar
• NelsonJCPapakostasGIAtypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trialsAm J Psychiatry200916698099119687129
   PubMed Web of Science ®Google Scholar
• GarattiniLCastelnuovoELanzeniDDurata e Costo delle visite in medicina generale. Il progetto DYSCO [Duration and cost of general practitioner visits. The DYSCO project]Farmeconomia Health Economics and Therapeutic Pathways20034109114 Italian.
   Google Scholar